NAMPT and colorectal carcinoma: Moreover, in CRC, (i) plasma level of visfatin could be used as a prognostic factor of poor response to 5-FU-included chemotherapy because a higher level of visfatin is observed in patients undergoing disease progression compared with the partial remission and stable disease groups [12], and (ii) inhibition of endogenous visfatin expression could downregulate the doxorubicin resistance of CRC cells [30].